|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT02972983 |
|
Date of registration:
|
21/11/2016 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
DASH |
|
Scientific title:
|
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia |
|
Date of first enrolment:
|
December 1, 2016 |
|
Target sample size:
|
102 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02972983 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Canada
| | | | | | | |
|
Contacts
|
|
Name:
|
Todd C Lee, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
McGill University Health Centre/Research Institute of the McGill University Health Centre |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patient has a methicillin susceptible Staphylococcus aureus bacteremia.
Exclusion Criteria:
- Underlying terminal illness
- Significant contraindication to beta-lactam therapy (i.e. severe allergy, severe
adverse drug reaction)
- Expected death before 5 days
- Microbiologically confirmed need for concomitant VANCOMYCIN or DAPTOMYCIN
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Bacteremia
|
|
Methicillin Susceptible Staphylococcus Aureus Septicemia
|
|
Intervention(s)
|
|
Drug: Daptomycin
|
|
Other: Placebo
|
|
Primary Outcome(s)
|
|
Blood culture clearance
[Time Frame: 5 days]
|
|
Secondary Outcome(s)
|
|
Metastatic infection
[Time Frame: 30 days]
|
|
Recurrent infection
[Time Frame: 30 days]
|
|
Mortality
[Time Frame: 30 days]
|
|
Adverse Reactions
[Time Frame: 5 days]
|
|
Intensive care admission
[Time Frame: 30 days]
|
|
Secondary ID(s)
|
|
2017-2666
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|